OncoMatch/Clinical Trials/NCT07378436
A Clinical Study of GK02 in Malignant Ascites
Is NCT07378436 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies GK02 for malignant ascites caused by advanced solid tumors.
Treatment: GK02 — A single-arm, single-center, open-label clinical study comprising three cohorts, evaluating the safety, preliminary efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) characteristics of autologous tumor-reactive T cells (GK02) derived from malignant ascites caused by advanced solid tumors. The trial initially plans to enroll 9 subjects with malignant ascites caused by advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Patients with advanced solid tumors confirmed by histology or pathology
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: any antitumor therapy
failed at least second-line treatment (treatment failure is defined as progression after treatment or intolerance after treatment)
Cannot have received: peritoneal treatment for malignant ascites
No peritoneal treatment for malignant ascites has been carried out within 14 days prior to the collection of malignant ascites
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify